JB Chemicals & Pharmaceuticals Limited — PPTs, 14-05-2025: Investor Presentation

1. Financial Highlights:

JB Pharma’s revenue rose 12% to INR 3,918 Cr in FY25, driven by a 20% jump in Domestic formulations (INR 2,269 Cr) and 4% growth in International business (INR 1,649 Cr). Q4 revenue grew 10% YoY to INR 949 Cr, led by Domestic sales (INR 519 Cr, +11%) and CDMO rebounds. Operating EBITDA increased 16% to INR 1,087 Cr, boosting margins to 27.7%. PAT climbed 19% to INR 660 Cr, aided by margin expansion and lower finance costs. ROCE improved sharply to 32% from 27%. The company ended with a net cash position of INR 689 Cr and robust operating cash flow of INR 903 Cr, reflecting strong cash conversion.

2. Strategic Initiatives & Growth Drivers:

The focus on accelerating Domestic and CDMO businesses, which now contribute 69% of revenues, remains central. Expansion of the chronic care portfolio, covering hypertension, heart failure, and probiotics (75% of Domestic sales), supports future growth. Continuous brand lifecycle management, digital integration, and launches in lozenges and OTC categories reinforce long-term momentum. Pan-India GTM strategy and enhanced field force productivity aim to drive sustained market share gains.

3. Business Developments:

Five recent acquisitions have strengthened cardiology, pediatrics, ophthalmology, and gastro portfolios. The CDMO segment, among the world’s top 5 lozenge manufacturers, rebounded strongly in H2 with new commercial projects. International formulations posted double-digit growth in Russia and branded generics exports. Manufacturing expansion includes ~INR 450 Cr capex across five advanced Indian facilities producing 10 dosage forms.

4. Market Position & Competitive Advantage:

Ranking #22 in the Indian Pharmaceutical Market with 6 brands in the top 300, JB Pharma holds a strong #8 spot in cardiac therapy. It delivers a 17% CAGR versus the market’s 8%, powered by a diversified portfolio and strong brands such as Cilacar (INR 785 Cr) and Metrogyl (INR 342 Cr). A prescription network of 3.45 lakh doctors and robust manufacturing plus R&D capabilities reinforce its competitive edge.

5. Investor Implications:

Robust revenue and margin expansion alongside high ROCE and cash flow conversion highlight strong growth potential. The focus on chronic therapies, brand strengthening, and CDMO diversification supports business resilience. Execution risks remain around sustained margin gains and integration of acquisitions, but operational strength and strategic clarity inspire confidence. Improved governance and ESG profile add to the company’s investment appeal.